Business
Envoy Medical Reports Full Year 2025 Financial Results
Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stageStrengthened balance sheet by extinguishing $32 million in debtSubsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH)...
About this update from Envoy Medical, Inc.
[{"type":"text","content":"Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Strengthened balance sheet by extinguishing $32 million in debt","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implant","length":224,"tagName":"p","attribs":{}},{"type":"text","content":"White Bear Lake, Minnesota--(Newsfile Corp. - March 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the full year ended December 31, 2025, as well as other subsequent events.","length":356,"tagName":"p"},{"type":"text","content":"Corporate and Financial Highlights for 2025:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Extinguished over $32 Million in Debt, Strengthening Balance Sheet","length":66,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial","length":97,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":431,"olType":false},{"type":"text","content":"Highlights Subsequent to 2025 Year End:","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed enrollment of a 56-patient U.S. pivotal trial for the fully implanted Acclaim® Cochlear Implant","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strengthened balance sheet with up to $78M public offering ($30M received, $48M potential from warrants)","leng...